Skip to search formSkip to main contentSkip to account menu

Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100

Known as: IMCgp100, ImmTAC-gp100 
A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Immune Mobilising Monoclonal TCRs Against Cancer (ImmTAC) molecules are a new class of bi-specific biologic specifically designed… 
2017
2017
IMCgp100, a first in class immunotherapy, is a T cell redirecting bispecific biologic comprising an affinity enhanced T-cell… 
2017
2017
IMCgp100, a first in class immunotherapy, is a T cell redirecting bispecific biologic comprising an affinity enhanced T-cell… 
2016
2016
For years cancer therapies were mainly concentrated around surgery, chemotherapy and radiotherapy. Recently, a new domain has… 
2016
2016
Immunotherapy strategies that are able to induce T cell infiltration into tumors and activate a cytotoxic T cell response have… 
2015
2015
Immunocore of Abingdon, UK, secured a record $320 million in a series A round in July. It is Europe’s largest-ever venture round… 
2015
2015
Immunocore of Abingdon, UK, secured a record $320 million in a series A round in July. It is Europe’s largest-ever venture round…